Reaching Patients Where They Are: Moving CGT Care into the Community

Joe DePinto, head of cell, gene, and advanced therapies at McKesson, explains that as cell and gene therapies rapidly advance, shrinking the nation’s growing “CGT deserts” by expanding capabilities in community care settings is essential to ensure that breakthrough treatments reach patients equitably—not just those living near major academic medical centers.

Cell and gene therapy (CGT) research and development continues to advance at a remarkable pace. The late-stage pipeline remains robust in oncology, while also expanding into new disease states where therapies could benefit much larger patient populations. Scientific advancements and growing clinical evidence are accelerating the transition of these therapies from investigational to real-world use.

Despite the...